Function Health's Series B Financing Tops $450M

Function Health has pushed its Series B financing above $450M. The company officially announced a $298M round in November 2025, while private-market data from Forge now reports 2 additional Series B tranches dated July 30, 2026, worth $94.11M and $65.08M.

Together, those figures put Function Health's Series B financing at approximately $457.19M. That is an important distinction from the intake headline: the evidence supports cumulative financing above $450M, not a newly announced standalone $450M round. Forge lists the latest extension investors as undisclosed and reports a $2.94B post-money valuation, up from the $2.5B valuation attached to the original round.

The larger signal is what investors appear to be funding. Function Health is moving beyond a direct-to-consumer lab-testing membership toward a connected platform spanning testing, imaging, mobile specimen collection, longitudinal data and medical intelligence. That is a much bigger operating challenge, but it is also a more consequential product thesis.

What Happened

Function Health's November 2025 announcement described an oversubscribed $298M Series B led by Redpoint Ventures. The round included a16z, Aglaé Ventures, Alumni Ventures, Battery Ventures, NFDG, FirstMark, Menlo Ventures, QuantumLight, Samsung Next, Seedcamp, Wisdom Ventures and a long list of strategic and individual backers.

Forge now reports 2 further Series B tranches completed on July 30, 2026. The $94.11M Series B-2 and $65.08M Series B-3 total $159.19M. Added to the official $298M financing, the broader Series B reaches about $457.19M. No official Function Health announcement for the extensions was found, so the new amounts and valuation should remain attributed to Forge, and the extension investors should remain described as undisclosed.

Function Health's earlier announcement tied its funding to expansion and the development of Medical Intelligence. The company has not publicly detailed a separate use-of-proceeds plan for the July 2026 extensions, which means any claim that the new capital is earmarked for a particular acquisition, market or product would be speculation.

Why This Matters

Healthcare has no shortage of data. The shortage is coherent, longitudinal context that an ordinary person can understand and use with qualified clinicians. Function Health's bet is that a consumer platform can make routine testing, imaging and health records feel like parts of one system instead of unrelated receipts from separate visits.

The company currently offers a $365 first-year membership with access to 160+ lab tests, longitudinal tracking and clinician-reviewed insights. Function says it operates through more than 2,000 U.S. lab locations and has delivered more than 75M results to members. Those are company-reported metrics, but they show the scale of the data and logistics problem the business is trying to manage.

Scale matters here because testing is only the entry point. Function Health has added advanced imaging through its acquisition of Ezra and mobile specimen collection through its 2026 acquisition of Getlabs. Each expansion brings more data and more operational complexity into the same member experience.

The Product Bet Behind the Capital

Function Health describes Medical Intelligence as a system designed to connect labs, imaging, wearables, IoT signals, medical records and research. Its current feature set includes Private AI Chat, personalized Protocols and the ability to upload previous health records into a secure vault. The company says clinical expertise remains part of the system rather than being replaced by software.

That positioning is important. Function Health identifies itself as a healthcare technology company, not a laboratory or medical provider, and it says its service does not diagnose disease or replace medical care. Its commercial opportunity therefore depends on making health information more accessible and useful while maintaining the privacy, clinical boundaries and scientific discipline that sensitive data demands.

Jonathan Swerdlin, Co-Founder and CEO, leads the company alongside a founding group that includes Pranitha Patil, Mark Hyman, M.D., Seth Weisfeld and Dan Swerdlin. Ziad Sultan, the company's Chief Product and Technology Officer and a former Spotify personalization executive, is responsible for helping turn an expanding stream of medical information into a product people can navigate.

What the Financing Signals

Function Health's cumulative Series B is a bet on preventive health as consumer infrastructure. Investors are not merely financing another dashboard for lab results. They are supporting an attempt to connect collection, diagnostics, imaging, longitudinal records and software intelligence under one membership relationship.

The strategic question is whether Function Health can translate that breadth into better decisions rather than more measurements. More tests can create visibility, but more data is not automatically more clarity. The company's defensibility will depend on the quality of its interpretation, the trustworthiness of its clinical and privacy controls, and the usefulness of the actions members can take with their healthcare providers.

The financing gives Function Health room to keep building that system. It also raises the standard by which the company should be judged. A platform promising proactive health at scale has to prove that its product can stay understandable, responsible and useful as the data grows faster than any individual can reasonably process alone.